Company expects EMA decision on YUVIWEL in Q4 2026
Ascendis plans to initiate Phase 3 trial of TransCon CNP for hypochondroplasia in H2 2026
Company expects to start Phase 3 trial of TransCon CNP + TransCon hGH in pediatric achondroplasia in Q4 2026
Overview
Denmark-based biopharma's Q2 product revenue rose 105% yr/yr, driven by TransCon product demand
Company posted net profit of €207 mln, reversing prior-year loss
Growth supported by YORVIPATH sales and €158 mln PRV sale
Result drivers
YORVIPATH demand - Co said Q2 revenue growth was driven by consistent new patient demand for YORVIPATH in the U.S. and expansion in over 35 countries
PRV sale - Q2 operating profit benefited from €158 mln in cash from sale of Rare Pediatric Disease Priority Review Voucher
Commercial expansion - Higher selling, general, and administrative expenses due to continued impact from commercial expansion, including global launch activities
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 20 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 32 three months ago.
ASND•
